GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Standalone Financial Statements for the year ended March 31, 2022 134 Note 14 : Bank balances other than cash and cash equivalents ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Earmarked Balances: Unclaimed dividend accounts 18,28.05 19,86.36 Term deposits with original maturity period of more than three months but less than twelve months 2179,10.00 732,00.00 Margin money 94.02 91.12 2198,32.07 752,77.48 Note 15 : Current financial assets - Others ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 (Unsecured considered good) Receivable from group companies 55,11.32 11,38.56 Interest accrued on deposits with banks 7,62.86 7,50.06 Advances recoverable 31.65 31.65 63,05.83 19,20.27 Note 16 : Other current assets ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Balances with Government Authorities 9,72.41 46,34.42 Advance to Creditors 18,35.40 9,82.18 Prepayments and Prepaid Expenses 12,77.25 13,49.57 Others 4,03.36 5,72.29 44,88.42 75,38.46 Note 17 : Assets classified as held for sale ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Freehold Land and Building 9.60 9.60 Plant and Machinery (Refer Note (a) below) 1.63 1.63 Assets at Vemgal location (Refer Note (b) below) - 180,00.61 11.23 180,11.84 Notes:- (a) The amount includes Plant and Machinery from Mysore and Bangalore site held for sale. (b) Assets at Vemgal location held for sale during the previous year ended March 31, 2021 consequent to the binding sale agreement entered into by the Company .The Company has received all relevant statutory and other approvals during the year and transaction has been concluded in December 2021.